Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence

Breast cancer represents the number one global cancer burden in women and the hormone receptor (HR)-positive subtype comprises approximately 70% of breast cancers. Unfortunately, acquired resistance ultimately occurs in almost all cases, even though cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...

Full description

Bibliographic Details
Main Authors: Kamal Pandey, Nahee Park, Kyung-Soon Park, Jin Hur, Yong Bin Cho, Minsil Kang, Hee-Jung An, Sewha Kim, Sohyun Hwang, Yong Wha Moon
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
CDK4/6
CDK2
hormone receptor-positive breast cancer
drug resistance
C-MYC
Online Access:https://www.mdpi.com/2072-6694/12/12/3566

Similar Items

Similar Items